OPKO Health (OPK) Financials

$1.26 -0.01 (-0.79%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.27 +0.01 (+0.79%)

As of 05/23/2025 07:51 PM Eastern

Annual Income Statements for OPKO Health

This table shows OPKO Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-53	-189	-328	-30	31	-315	-153	-305	-48	-30	-172
Consolidated Net Income / (Loss)	-53	-189	-328	-30	31	-315	-153	1,443	-48	-31	-175
Net Income / (Loss) Continuing Operations	-53	-189	-328	-30	31	-315	-153	1,443	-48	-31	-175
Total Pre-Tax Income	-10	-184	-392	-14	49	-305	-177	-272	-97	-138	-171
Total Operating Income	-152	-157	-226	19	58	-274	-171	-276	-97	-98	-146
Total Gross Profit	219	318	288	582	541	329	386	1,129	506	256	43
Total Revenue	713	863	1,004	1,775	1,435	902	990	1,749	1,117	492	91
Operating Revenue	713	863	1,004	1,775	1,435	902	990	1,749	1,117	492	91
Total Cost of Revenue	495	545	716	1,193	894	572	605	620	611	235	48
Operating Cost of Revenue	495	545	716	1,193	894	572	605	620	611	235	48
Total Operating Expenses	371	475	514	563	483	604	557	-344	603	355	189
Selling, General & Admin Expense	304	301	373	469	356	343	358	415	407	197	58
Research & Development Expense	105	90	74	77	75	118	126	126	114	99	96
Amortization Expense	83	86	88	50	56	65	68	71	64	28	11
Other Special Charges / (Income)	-121	-1.04	-20	-33	-3.99	-15	-17	-3.42	17	5.05	24
Total Other Income / (Expense), net	142	-27	-165	-33	-9.03	-31	-6.07	4.52	-0.27	-40	-25
Interest Expense	47	14	12	19	22	22	12	6.60	7.43	8.42	12
Interest & Investment Income	8.43	3.98	1.98	0.03	0.15	1.71	1.24	0.61	0.48	0.26	0.77
Other Income / (Expense), net	181	-18	-155	-14	13	-11	4.58	11	6.68	-31	-14
Income Tax Expense	43	4.44	-63	15	18	7.06	-39	19	-56	-114	0.02
Other Gains / (Losses), net	-0.02	-0.11	-0.38	-0.63	-0.48	-2.90	-14	-14	-7.65	-7.11	-3.59
Basic Earnings per Share	($0.08)	($0.25)	($0.46)	($0.05)	$0.05	($0.53)	($0.27)	($0.55)	($0.09)	($0.06)	($0.41)
Weighted Average Basic Shares Outstanding	694.02M	751.77M	719.06M	648.08M	640.66M	595.45M	563.14M	559.16M	550.85M	488.07M	422.01M
Weighted Average Diluted Shares Outstanding	671.55M	696.99M	772.65M	681.46M	640.66M	595.45M	563.14M	559.16M	555.61M	488.07M	422.01M
Weighted Average Basic & Diluted Shares Outstanding	671.55M	696.99M	772.65M	681.46M	640.66M	595.45M	563.14M	559.16M	550.85M	488.07M	422.01M

This table shows OPKO Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-68	14	25	-10	-82	-66	-84	-20	-18	-85	-86
Consolidated Net Income / (Loss)	-68	14	25	-10	-82	-66	-84	-20	-18	-85	-86
Net Income / (Loss) Continuing Operations	-68	14	25	-10	-82	-66	-84	-20	-18	-85	-86
Total Pre-Tax Income	-73	35	48	-11	-83	-72	-78	-16	-17	-102	-126
Total Operating Income	-67	-33	14	-62	-71	-69	-64	7.03	-31	-55	-88
Total Gross Profit	43	85	40	52	42	45	48	126	99	56	31
Total Revenue	150	184	174	182	174	182	179	265	238	185	180
Operating Revenue	150	184	174	182	174	182	179	265	238	185	180
Total Cost of Revenue	107	99	134	131	132	137	131	139	138	129	148
Operating Cost of Revenue	107	99	134	131	132	137	131	139	138	129	148
Total Operating Expenses	110	118	26	113	114	114	112	119	130	111	119
Selling, General & Admin Expense	59	67	98	69	70	73	72	80	76	74	80
Research & Development Expense	31	30	29	24	22	19	19	18	33	20	19
Amortization Expense	20	20	20	20	21	21	22	22	21	22	21
Total Other Income / (Expense), net	-6.21	68	34	51	-12	-3.45	-14	-23	14	-47	-39
Interest Expense	15	14	17	8.18	7.69	3.45	3.38	3.28	3.39	3.30	3.02
Interest & Investment Income	4.68	4.29	2.93	0.39	0.81	0.91	0.97	1.08	1.03	1.14	0.67
Other Income / (Expense), net	4.58	78	49	59	-4.84	-0.90	-12	-21	16	-45	-36
Income Tax Expense	-5.77	21	24	-0.28	-1.35	-6.02	6.08	3.15	1.23	-17	-40
Other Gains / (Losses), net	-0.01	-0.01	-0.00	-0.00	-0.00	-0.01	-0.02	-0.04	-0.04	-0.02	-0.04
Basic Earnings per Share	($0.10)	$0.01	$0.04	($0.01)	($0.12)	($0.09)	($0.11)	($0.03)	($0.02)	($0.13)	($0.11)
Weighted Average Basic Shares Outstanding	671.58M	694.02M	694.62M	697.21M	706.88M	751.77M	751.53M	751.73M	751.51M	719.06M	750.40M
Weighted Average Diluted Shares Outstanding	793.05M	671.55M	998.36M	697.38M	696.99M	696.99M	751.53M	773.06M	772.65M	772.65M	772.69M
Weighted Average Basic & Diluted Shares Outstanding	793.05M	671.55M	682.48M	697.38M	696.99M	696.99M	773.06M	773.06M	772.65M	772.65M	772.69M

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	350	-57	18	62	-13	-11	4.97	-77	-25	97	-89
Net Cash From Operating Activities	-183	-28	-95	38	39	-173	-109	-92	32	164	-90
Net Cash From Continuing Operating Activities	-183	-28	-95	38	39	-173	-109	-92	32	164	-90
Net Income / (Loss) Continuing Operations	-53	-189	-328	-30	31	-315	-153	-305	-48	-31	-175
Consolidated Net Income / (Loss)	-53	-189	-328	-30	31	-315	-153	-305	-48	-31	-175
Depreciation Expense	98	105	109	79	85	94	97	102	97	42	15
Amortization Expense	1.97	1.22	1.16	0.79	0.85	1.00	0.19	0.22	0.24	1.21	2.01
Non-Cash Adjustments To Reconcile Net Income	-273	32	159	-13	0.07	58	57	-9.30	1.61	66	45
Changes in Operating Assets and Liabilities, net	43	22	-35	1.54	-77	-9.96	-110	120	-18	86	22
Net Cash From Investing Activities	352	-18	91	36	-18	-13	-26	-47	-21	-99	-5.68
Net Cash From Continuing Investing Activities	352	-18	91	36	-18	-13	-26	-47	-21	-99	-5.68
Purchase of Property, Plant & Equipment	-25	-16	-25	-32	-34	-13	-28	-47	-19	-11	-4.73
Acquisitions	0.00	0.00	-1.76	-4.00	0.00	0.00	-	-	-5.00	-84	-1.68
Purchase of Investments	0.00	-5.00	0.00	-2.00	0.00	-1.20	-1.00	-9.63	-30	-4.38	-0.59
Sale of Property, Plant & Equipment	0.24	2.71	1.95	66	0.25	0.67	1.22	7.27	1.40	0.00	0.00
Divestitures	210	0.00	0.00	-	-	-	-	-	16	-	-
Sale and/or Maturity of Investments	167	0.36	115	8.08	15	0.00	1.52	2.21	16	0.00	0.00
Net Cash From Financing Activities	184	-11	23	-10	-35	175	141	61	-35	33	7.26
Net Cash From Continuing Financing Activities	184	-11	23	-10	-35	175	141	61	-35	33	7.26
Repayment of Debt	-665	-683	-1,036	-1,696	-1,144	-396	-35	-34	-66	-254	-28
Repurchase of Common Equity	-90	0.00	0.00	-	-	-	-	-	-	-	-
Issuance of Debt	939	672	1,060	1,685	1,108	495	82	92	22	261	26
Other Financing Activities, net	-0.21	-0.27	-0.77	1.08	0.76	-0.00	1.17	2.13	-	-	-6.44
Effect of Exchange Rate Changes	-3.16	0.39	-0.34	-1.44	0.69	-0.48	-	0.47	-1.01	-1.12	-0.10
Cash Interest Paid	21	8.14	7.42	8.52	11	12	2.08	1.31	2.89	4.57	6.28
Cash Income Taxes Paid	10	3.71	8.04	5.97	-0.90	2.67	-1.41	5.42	-27	4.88	0.95

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	4.06	26	379	-35	-20	-43	31	-2.72	-42	-28	-30
Net Cash From Operating Activities	-35	-44	-77	-26	-36	-38	33	-0.37	-23	-32	-32
Net Cash From Continuing Operating Activities	-35	-44	-77	-26	-36	-38	33	-0.37	-23	-32	-32
Net Income / (Loss) Continuing Operations	-68	14	25	-10	-82	-66	-84	-20	-18	-85	-86
Consolidated Net Income / (Loss)	-68	14	25	-10	-82	-66	-84	-20	-18	-85	-86
Depreciation Expense	23	24	24	24	26	26	26	27	26	26	26
Amortization Expense	0.43	0.65	0.38	0.43	0.52	0.31	0.31	0.30	0.30	0.30	0.29
Non-Cash Adjustments To Reconcile Net Income	5.23	-111	-120	-50	6.94	6.80	12	18	-4.21	43	40
Changes in Operating Assets and Liabilities, net	3.92	28	-6.33	8.81	13	-4.91	79	-26	-27	-16	-13
Net Cash From Investing Activities	41	116	248	-7.16	-4.40	-1.42	-3.57	-5.49	-7.72	-7.87	-4.68
Net Cash From Continuing Investing Activities	41	116	248	-7.16	-4.40	-1.42	-3.57	-5.49	-7.72	-7.87	-4.68
Purchase of Property, Plant & Equipment	-3.19	-5.41	-7.94	-7.22	-4.44	-3.02	-4.20	-6.01	-3.04	-6.34	-7.61
Purchase of Investments	-8.00	1.45	-1.45	-	0.00	-	-	-	-5.00	-	-
Sale of Property, Plant & Equipment	0.07	0.07	-	-	-	1.60	-	-	-	0.45	0.63
Sale and/or Maturity of Investments	52	120	47	0.06	0.05	-	-0.48	0.52	0.32	115	-
Net Cash From Financing Activities	-4.02	-40	206	-2.12	21	-3.75	2.11	3.46	-13	10	8.44
Net Cash From Continuing Financing Activities	-4.02	-40	206	-2.12	21	-3.75	2.11	3.46	-13	10	8.44
Repayment of Debt	-9.72	-35	-151	-156	-323	-160	-171	-173	-178	-156	-200
Repurchase of Common Equity	0.00	-16	-24	-	-50	-	-	-	0.00	-	-
Issuance of Debt	5.61	11	381	154	394	156	173	177	165	166	209
Other Financing Activities, net	0.09	-	-	-	-	0.00	0.03	-	-	-0.09	-0.46
Effect of Exchange Rate Changes	2.11	-5.56	2.64	0.65	-0.89	0.72	-1.13	-0.33	1.12	1.70	-1.15
Cash Interest Paid	14	7.90	9.47	0.39	3.13	-2.61	6.54	0.37	3.83	0.40	3.47
Cash Income Taxes Paid	2.06	6.21	2.23	0.51	1.06	4.54	-1.51	0.21	0.48	3.57	-0.18

This table presents OPKO Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	2,200	2,012	2,167	2,400	2,473	2,309	2,451	2,590	2,767	2,799	-
Total Current Assets	662	309	395	823	523	324	318	349	484	454	-
Cash & Equivalents	432	-	153	135	72	85	96	91	169	194	-
Accounts Receivable	118	123	127	260	286	135	144	166	220	194	-
Inventories, net	57	66	74	87	132	53	42	49	47	40	-
Prepaid Expenses	55	25	40	27	32	51	35	43	47	27	-
Plant, Property, & Equipment, net	70	75	83	80	141	0.00	145	147	123	132	-
Total Noncurrent Assets	1,468	1,627	1,690	1,497	1,809	1,985	1,989	2,095	2,160	2,213	-
Long-Term Investments	55	16	28	11	16	21	31	41	41	35	-
Goodwill	529	598	596	521	681	672	700	717	705	743	-
Intangible Assets	812	935	1,019	912	1,065	529	1,250	1,331	1,409	1,430	-
Other Noncurrent Operating Assets	73	77	47	54	48	764	7.22	5.62	5.76	4.84	-
Total Liabilities & Shareholders' Equity	2,200	2,012	2,167	2,400	2,473	2,309	2,451	2,590	2,767	2,799	-
Total Liabilities	835	622	606	715	802	695	660	746	675	819	-
Total Current Liabilities	193	200	213	330	375	249	288	312	263	252	-
Short-Term Debt	15	27	37	15	-	9.62	37	12	12	11	-
Accounts Payable	47	70	67	82	101	63	47	74	53	73	-
Accrued Expenses	118	90	98	193	241	165	204	226	198	168	-
Other Current Liabilities	13	13	12	12	34	12	-	-	-	-	-
Total Noncurrent Liabilities	642	422	392	385	426	445	371	434	412	567	-
Long-Term Debt	419	214	210	188	222	211	57	29	44	49	-
Noncurrent Deferred & Payable Income Tax Liabilities	141	127	126	148	137	119	115	149	165	226	-
Other Noncurrent Operating Liabilities	82	81	55	48	67	115	199	256	202	292	-
Total Equity & Noncontrolling Interests	1,365	1,389	1,562	1,685	1,672	1,615	1,791	1,844	2,092	1,980	-
Total Preferred & Common Equity	1,365	1,389	1,562	1,685	1,672	1,615	1,791	1,844	2,092	1,980	-
Total Common Equity	1,365	1,389	1,562	1,685	1,672	1,615	1,791	1,844	2,092	1,980	-
Common Stock	3,488	3,441	3,430	3,229	3,159	3,150	3,010	2,895	2,851	2,711	-
Retained Earnings	-2,065	-2,012	-1,823	-1,512	-1,482	-1,511	-1,197	-1,049	-730	-705	-
Treasury Stock	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.91	-3.65	-
Accumulated Other Comprehensive Income / (Loss)	-56	-38	-43	-30	-4.23	-22	-20	-0.53	-27	-23	-

This table presents OPKO Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	2,128	2,256	1,980	1,974	2,057	2,159	2,170	2,225
Total Current Assets	738	630	358	391	357	434	406	414
Cash & Equivalents	436	406	41	76	139	108	111	181
Accounts Receivable	96	107	105	111	117	211	121	123
Inventories, net	64	59	60	59	69	74	75	71
Prepaid Expenses	54	57	32	25	32	41	99	39
Other Current Assets	87	-	-	-	-	-	-	0.00
Plant, Property, & Equipment, net	71	72	67	64	78	79	81	0.00
Total Noncurrent Assets	1,320	1,554	1,555	1,519	1,621	1,646	1,487	1,811
Long-Term Investments	13	101	101	41	19	28	41	78
Goodwill	477	536	530	531	594	597	597	573
Intangible Assets	569	836	854	875	953	782	804	835
Other Noncurrent Operating Assets	262	81	69	72	54	239	45	324
Total Liabilities & Shareholders' Equity	2,128	2,256	1,980	1,974	2,057	2,159	2,170	2,225
Total Liabilities	817	853	585	721	612	624	618	596
Total Current Liabilities	296	212	220	204	201	226	222	267
Short-Term Debt	113	13	22	23	30	29	24	94
Accounts Payable	59	63	82	71	67	88	81	50
Accrued Expenses	113	123	95	89	92	99	106	112
Other Current Liabilities	9.89	13	12	12	11	11	11	12
Total Noncurrent Liabilities	521	641	365	517	412	397	395	328
Long-Term Debt	323	424	176	323	213	212	211	142
Noncurrent Deferred & Payable Income Tax Liabilities	129	128	119	122	138	133	130	135
Other Noncurrent Operating Liabilities	68	89	70	72	60	52	54	52
Total Equity & Noncontrolling Interests	1,312	1,403	1,395	1,253	1,445	1,535	1,552	1,629
Total Preferred & Common Equity	1,312	1,403	1,395	1,253	1,445	1,535	1,552	1,629
Total Common Equity	1,312	1,403	1,395	1,253	1,445	1,535	1,552	1,629
Common Stock	3,491	3,524	3,548	3,393	3,438	3,435	3,432	3,427
Retained Earnings	-2,133	-2,079	-2,104	-2,094	-1,945	-1,861	-1,841	-1,738
Treasury Stock	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-
Accumulated Other Comprehensive Income / (Loss)	-45	-40	-47	-45	-46	-37	-38	-58

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-17.41%	-14.01%	-43.42%	23.64%	59.15%	-8.92%	-43.37%	56.49%	127.25%	439.49%	615.46%
EBITDA Growth	288.68%	74.86%	-422.11%	-46.18%	182.31%	-175.53%	57.77%	-2,456.56%	108.04%	39.43%	-421.55%
EBIT Growth	116.41%	54.18%	-8,002.34%	-93.15%	124.71%	-71.14%	37.35%	-195.91%	30.78%	18.62%	-483.48%
NOPAT Growth	3.16%	30.60%	-1,306.68%	-64.36%	119.20%	-60.08%	38.07%	-186.32%	1.96%	32.46%	-843.30%
Net Income Growth	71.82%	42.49%	-989.49%	-198.55%	109.71%	-105.78%	-110.60%	3,084.90%	-53.87%	82.00%	-52.65%
EPS Growth	0.00%	0.00%	0.00%	0.00%	109.43%	-96.30%	0.00%	0.00%	-66.67%	85.37%	0.00%
Operating Cash Flow Growth	-550.74%	70.38%	-348.30%	-2.89%	122.88%	-58.07%	-18.53%	-387.34%	-80.46%	281.48%	0.00%
Free Cash Flow Firm Growth	6,944.94%	90.48%	-131.59%	222.52%	75.83%	-29.74%	-1,384.41%	95.62%	89.72%	-339.41%	209.01%
Invested Capital Growth	-13.55%	-6.67%	-8.08%	-1.95%	4.41%	-1.64%	0.33%	-9.55%	6.94%	0.00%	-100.00%
Revenue Q/Q Growth	0.24%	-0.40%	-17.70%	-5.00%	23.20%	0.28%	-42.16%	79.11%	-8.58%	103.95%	3,554.73%
EBITDA Q/Q Growth	727.88%	30.25%	-12.94%	-57.43%	3,140.41%	-3.00%	42.98%	-111.08%	-85.49%	35.96%	-159.19%
EBIT Q/Q Growth	133.27%	14.68%	-11.23%	-95.90%	183.79%	-1.65%	24.35%	-49.08%	-90.64%	18.79%	-189.96%
NOPAT Q/Q Growth	19.10%	-9.62%	3.34%	-87.16%	150.54%	-8.92%	28.31%	-43.62%	-213.38%	19.93%	-71.44%
Net Income Q/Q Growth	60.20%	9.03%	-3.61%	-139.70%	126.82%	-13.02%	-110.53%	1,261.53%	-392.50%	63.66%	-28.72%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	127.78%	-10.42%	0.00%	0.00%	-225.00%	80.00%	0.00%
Operating Cash Flow Q/Q Growth	-3.45%	-31.01%	-37.53%	-51.00%	196.71%	-7.06%	-50.81%	-44.14%	521.05%	10.37%	0.00%
Free Cash Flow Firm Q/Q Growth	53.85%	93.96%	-142.83%	-52.51%	59.18%	-0.90%	-431.19%	94.45%	-21.01%	-77.14%	1,913.87%
Invested Capital Q/Q Growth	-1.55%	-0.73%	1.32%	-1.95%	0.03%	-2.92%	-2.10%	-12.42%	-2.31%	-1.81%	-100.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.64%	36.84%	28.70%	32.77%	37.69%	36.53%	38.94%	64.54%	45.28%	52.16%	47.33%
EBITDA Margin	18.06%	-7.91%	-27.05%	4.75%	10.91%	-21.11%	-6.98%	-9.36%	0.62%	-17.57%	-156.45%
Operating Margin	-21.32%	-18.18%	-22.53%	1.06%	4.02%	-30.38%	-17.29%	-15.81%	-8.64%	-20.03%	-159.97%
EBIT Margin	4.02%	-20.24%	-37.99%	0.27%	4.91%	-31.62%	-16.83%	-15.21%	-8.04%	-26.40%	-175.03%
Profit (Net Income) Margin	-7.46%	-21.87%	-32.70%	-1.70%	2.13%	-34.92%	-15.45%	82.54%	-4.33%	-6.39%	-191.60%
Tax Burden Percent	513.65%	102.47%	83.88%	214.92%	62.83%	103.27%	86.33%	-530.83%	49.95%	22.77%	102.11%
Interest Burden Percent	-36.13%	105.45%	102.64%	-290.55%	69.09%	106.95%	106.39%	102.25%	107.74%	106.29%	107.20%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	36.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.52%	-6.99%	-9.32%	0.73%	2.08%	-11.00%	-6.83%	-10.49%	-3.61%	-7.61%	-23.00%
ROIC Less NNEP Spread (ROIC-NNEP)	130.12%	-87.82%	-234.47%	-38.71%	-2.94%	-312.54%	46.71%	-1,345.46%	-15.55%	-52.30%	-1,008.77%
Return on Net Nonoperating Assets (RNNOA)	3.65%	-5.81%	-10.91%	-2.53%	-0.22%	-7.49%	-1.59%	83.85%	1.23%	4.43%	-17.01%
Return on Equity (ROE)	-3.86%	-12.80%	-20.23%	-1.80%	1.86%	-18.49%	-8.42%	73.36%	-2.38%	-3.17%	-40.01%
Cash Return on Invested Capital (CROIC)	7.01%	-0.09%	-0.90%	2.70%	-2.23%	-9.34%	-7.15%	-0.46%	-10.31%	-207.61%	177.00%
Operating Return on Assets (OROA)	1.36%	-8.37%	-16.70%	0.20%	2.95%	-11.98%	-6.61%	-9.93%	-3.23%	-9.28%	-22.93%
Return on Assets (ROA)	-2.53%	-9.04%	-14.38%	-1.24%	1.28%	-13.23%	-6.07%	53.90%	-1.74%	-2.25%	-25.10%
Return on Common Equity (ROCE)	-3.86%	-12.80%	-20.23%	-1.80%	1.86%	-18.49%	-8.42%	73.36%	-2.38%	-3.17%	-40.17%
Return on Equity Simple (ROE_SIMPLE)	-3.90%	-13.59%	-21.03%	-1.79%	1.83%	-19.50%	-8.54%	78.30%	-2.31%	-1.59%	0.00%
Net Operating Profit after Tax (NOPAT)	-106	-110	-158	13	37	-192	-120	-194	-68	-69	-102
NOPAT Margin	-14.93%	-12.73%	-15.77%	0.74%	2.57%	-21.27%	-12.10%	-11.07%	-6.05%	-14.02%	-111.98%
Net Nonoperating Expense Percent (NNEP)	-137.64%	80.83%	225.15%	39.44%	5.02%	301.54%	-53.53%	1,334.97%	11.94%	44.69%	985.77%
Return On Investment Capital (ROIC_SIMPLE)	-5.91%	-6.74%	-8.76%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	69.36%	63.16%	71.30%	67.23%	62.31%	63.47%	61.06%	35.46%	54.72%	47.84%	52.67%
SG&A Expenses to Revenue	42.66%	34.81%	37.11%	26.42%	24.77%	38.06%	36.19%	23.71%	36.45%	39.98%	63.57%
R&D to Revenue	14.75%	10.38%	7.36%	4.33%	5.25%	13.07%	12.68%	7.23%	10.19%	20.23%	104.91%
Operating Expenses to Revenue	51.96%	55.03%	51.23%	31.71%	33.67%	66.91%	56.23%	-19.65%	53.92%	72.19%	207.28%
Earnings before Interest and Taxes (EBIT)	29	-175	-381	4.83	70	-285	-167	-266	-90	-130	-160
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	129	-68	-272	84	157	-190	-69	-164	6.94	-86	-143
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.73	0.84	0.62	1.94	1.58	0.61	0.94	1.49	2.48	2.77	0.00
Price to Tangible Book Value (P/TBV)	40.81	0.00	0.00	12.97	0.00	2.36	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.41	1.35	0.96	1.85	1.84	1.08	1.70	1.57	4.64	11.14	47.58
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	86.53	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	1.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.72	0.85	0.63	1.88	1.54	0.63	0.94	1.51	2.60	2.93	0.00
Enterprise Value to Revenue (EV/Rev)	1.33	1.50	1.03	1.88	1.94	1.21	1.67	1.52	4.50	10.80	47.58
Enterprise Value to EBITDA (EV/EBITDA)	7.38	0.00	0.00	39.54	17.75	0.00	0.00	0.00	724.60	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	33.16	0.00	0.00	690.79	39.46	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	254.05	75.50	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	86.98	70.44	0.00	0.00	0.00	156.99	32.37	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	9.58	0.00	0.00	69.11	0.00	0.00	0.00	0.00	0.00	0.00	5.52
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.32	0.17	0.16	0.12	0.13	0.14	0.05	0.02	0.03	0.03	0.00
Long-Term Debt to Equity	0.31	0.15	0.13	0.11	0.13	0.13	0.03	0.02	0.02	0.02	0.00
Financial Leverage	0.03	0.07	0.05	0.07	0.08	0.02	-0.03	-0.06	-0.08	-0.08	0.02
Leverage Ratio	1.53	1.42	1.41	1.45	1.46	1.40	1.39	1.36	1.37	1.41	1.59
Compound Leverage Factor	-0.55	1.49	1.44	-4.22	1.01	1.49	1.48	1.39	1.47	1.50	1.71
Debt to Total Capital	24.13%	14.82%	13.65%	10.73%	11.72%	12.03%	5.02%	2.18%	2.59%	2.96%	0.00%
Short-Term Debt to Total Capital	0.83%	1.67%	2.02%	0.78%	0.00%	0.52%	1.98%	0.63%	0.56%	0.56%	0.00%
Long-Term Debt to Total Capital	23.29%	13.14%	11.63%	9.96%	11.72%	11.51%	3.04%	1.55%	2.04%	2.40%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	75.87%	85.18%	86.35%	89.27%	88.28%	87.97%	94.98%	97.82%	97.41%	97.04%	0.00%
Debt to EBITDA	3.37	-3.54	-0.91	2.40	1.42	-1.16	-1.37	-0.25	8.02	-0.70	0.00
Net Debt to EBITDA	-0.41	-1.90	-0.24	0.68	0.86	-0.60	0.48	0.56	-22.21	1.94	0.00
Long-Term Debt to EBITDA	3.25	-3.14	-0.77	2.23	1.42	-1.11	-0.83	-0.18	6.29	-0.57	0.00
Debt to NOPAT	-4.08	-2.20	-1.56	15.44	6.03	-1.15	-0.79	-0.21	-0.82	-0.88	0.00
Net Debt to NOPAT	0.49	-1.18	-0.41	4.36	3.64	-0.60	0.28	0.47	2.28	2.44	0.00
Long-Term Debt to NOPAT	-3.94	-1.95	-1.33	14.32	6.03	-1.10	-0.48	-0.15	-0.65	-0.71	0.00
Altman Z-Score	0.03	-0.07	-0.24	2.86	1.89	-0.05	1.04	1.99	4.63	3.77	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.39%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.43	1.55	1.85	2.49	1.39	1.30	1.10	1.12	1.84	1.80	0.00
Quick Ratio	2.85	0.62	1.31	1.20	0.95	0.88	0.83	0.82	1.48	1.54	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	99	-1.45	-15	48	-39	-163	-126	-8.46	-193	-1,881	786
Operating Cash Flow to CapEx	-740.83%	-207.91%	-420.69%	0.00%	118.06%	-1,429.35%	-409.77%	-234.58%	186.90%	1,512.30%	-1,909.15%
Free Cash Flow to Firm to Interest Expense	2.09	-0.11	-1.26	2.56	-1.80	-7.57	-10.56	-1.28	-26.01	-223.41	64.07
Operating Cash Flow to Interest Expense	-3.87	-2.09	-7.90	2.03	1.80	-8.02	-9.18	-13.95	4.31	19.48	-7.37
Operating Cash Flow Less CapEx to Interest Expense	-4.39	-3.09	-9.77	3.82	0.28	-8.58	-11.42	-19.90	2.01	18.19	-7.76
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.41	0.44	0.73	0.60	0.38	0.39	0.65	0.40	0.35	0.13
Accounts Receivable Turnover	5.91	6.89	5.19	6.50	6.82	6.48	6.40	9.07	5.40	0.00	0.00
Inventory Turnover	8.08	7.80	8.92	10.90	9.63	11.96	13.20	12.84	14.07	0.00	0.00
Fixed Asset Turnover	9.80	10.91	12.35	16.11	0.00	0.00	6.80	12.98	8.78	0.00	0.00
Accounts Payable Turnover	8.47	7.98	9.61	13.05	10.95	10.42	9.94	9.71	9.71	0.00	0.00
Days Sales Outstanding (DSO)	61.78	52.98	70.32	56.14	53.52	56.36	57.02	40.26	67.64	0.00	0.00
Days Inventory Outstanding (DIO)	45.20	46.77	40.93	33.47	37.91	30.52	27.66	28.42	25.94	0.00	0.00
Days Payable Outstanding (DPO)	43.08	45.73	37.99	27.98	33.35	35.04	36.73	37.57	37.57	0.00	0.00
Cash Conversion Cycle (CCC)	63.90	54.02	73.26	61.64	58.08	51.83	47.95	31.11	56.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,313	1,519	1,627	1,770	1,806	1,729	1,758	1,753	1,938	1,812	0.00
Invested Capital Turnover	0.50	0.55	0.59	0.99	0.81	0.52	0.56	0.95	0.60	0.54	0.21
Increase / (Decrease) in Invested Capital	-206	-108	-143	-35	76	-29	5.73	-185	126	1,812	-888
Enterprise Value (EV)	951	1,297	1,032	3,334	2,781	1,093	1,652	2,650	5,031	5,310	4,337
Market Capitalization	1,003	1,167	966	3,277	2,647	978	1,685	2,741	5,185	5,477	4,337
Book Value per Share	$2.00	$1.80	$2.02	$2.47	$2.49	$2.43	$3.20	$3.30	$3.75	$3.63	$0.00
Tangible Book Value per Share	$0.04	($0.19)	($0.07)	$0.37	($0.11)	$0.62	($0.28)	($0.37)	($0.04)	($0.36)	$0.00
Total Capital	1,800	1,631	1,809	1,888	1,894	1,836	1,886	1,885	2,147	2,040	0.00
Total Debt	434	242	247	203	222	221	95	41	56	60	0.00
Total Long-Term Debt	419	214	210	188	222	211	57	29	44	49	0.00
Net Debt	-52	130	66	57	134	115	-33	-91	-154	-168	0.00
Capital Expenditures (CapEx)	25	14	23	-34	33	12	27	39	17	11	4.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)	52	41	64	373	75	-0.91	-30	-43	64	20	0.00
Debt-free Net Working Capital (DFNWC)	484	137	218	508	148	85	67	49	232	214	0.00
Net Working Capital (NWC)	469	109	181	493	148	75	29	37	220	202	0.00
Net Nonoperating Expense (NNE)	-53	79	170	43	6.24	123	33	-1,637	-19	-38	73
Net Nonoperating Obligations (NNO)	-52	130	66	85	134	115	-33	-91	-154	-168	0.00
Total Depreciation and Amortization (D&A)	100	107	110	80	86	95	98	102	97	43	17
Debt-free, Cash-free Net Working Capital to Revenue	7.30%	4.73%	6.42%	21.02%	5.26%	-0.10%	-2.99%	-2.44%	5.69%	4.07%	0.00%
Debt-free Net Working Capital to Revenue	67.87%	15.83%	21.67%	28.61%	10.29%	9.37%	6.75%	2.79%	20.79%	43.44%	0.00%
Net Working Capital to Revenue	65.76%	12.67%	18.03%	27.78%	10.29%	8.31%	2.97%	2.11%	19.71%	41.11%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.08)	($0.25)	($0.46)	($0.05)	$0.05	($0.53)	($0.27)	($0.55)	($0.05)	($0.06)	($0.41)
Adjusted Weighted Average Basic Shares Outstanding	694.02M	751.77M	719.06M	648.08M	670.04M	669.83M	563.14M	559.47M	558.22M	545.70M	451.63M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.46)	($0.05)	$0.05	($0.53)	($0.27)	($0.55)	($0.05)	($0.06)	($0.41)
Adjusted Weighted Average Diluted Shares Outstanding	671.55M	696.99M	719.06M	648.08M	670.04M	669.83M	563.14M	559.47M	558.22M	545.70M	451.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.05	($0.53)	$0.00	($0.55)	($0.05)	($0.06)	($0.41)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	671.55M	696.99M	772.65M	681.46M	640.66M	595.45M	615.60M	559.16M	550.85M	488.07M	422.01M
Normalized Net Operating Profit after Tax (NOPAT)	-191	-111	-172	-10	34	-138	-116	-187	-56	-65	-85
Normalized NOPAT Margin	-26.85%	-12.81%	-17.16%	-0.57%	2.39%	-15.25%	-11.75%	-10.67%	-4.99%	-13.30%	-93.21%
Pre Tax Income Margin	-1.45%	-21.35%	-38.99%	-0.79%	3.39%	-33.81%	-17.90%	-15.55%	-8.66%	-28.06%	-187.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.60	-12.94	-31.64	0.26	3.21	-13.25	-14.01	-40.29	-12.10	-15.42	-13.01
NOPAT to Interest Expense	-2.24	-8.14	-13.14	0.70	1.68	-8.92	-10.08	-29.32	-9.10	-8.19	-8.32
EBIT Less CapEx to Interest Expense	0.08	-13.95	-33.52	2.05	1.69	-13.81	-16.25	-46.23	-14.40	-16.71	-13.40
NOPAT Less CapEx to Interest Expense	-2.76	-9.14	-15.01	2.49	0.15	-9.48	-12.32	-35.26	-11.40	-9.48	-8.71
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.32%	1.54%
Augmented Payout Ratio	-169.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.32%	1.54%

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-13.66%	0.95%	-2.78%	-31.36%	-26.89%	-1.85%	-0.64%	-14.35%	-27.84%	-53.82%	-53.41%
EBITDA Growth	22.61%	259.49%	277.16%	72.92%	-512.78%	40.42%	49.32%	122.86%	126.37%	-73.87%	-277.33%
EBIT Growth	17.98%	164.24%	182.74%	80.39%	-421.39%	30.07%	38.75%	82.91%	80.22%	-62.61%	-446.89%
NOPAT Growth	6.02%	72.49%	116.21%	-977.86%	-133.61%	-24.92%	26.66%	165.42%	57.76%	12.39%	-277.65%
Net Income Growth	17.38%	121.10%	129.47%	47.53%	-348.00%	22.00%	1.88%	80.68%	67.05%	-15.53%	-399.56%
EPS Growth	0.00%	0.00%	127.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	2.85%	-15.97%	-332.80%	-7,142.47%	-57.05%	-21.11%	202.71%	96.82%	-14.06%	-460.34%	-196.53%
Free Cash Flow Firm Growth	35.18%	220.04%	552.94%	4,812.18%	-93.70%	-42.43%	-77.42%	-102.35%	929.17%	1,256.17%	305.76%
Invested Capital Growth	-5.27%	-13.55%	-12.82%	-18.27%	-4.77%	-6.67%	-4.75%	0.64%	-18.14%	-8.08%	-11.05%
Revenue Q/Q Growth	-18.34%	5.76%	-4.70%	4.89%	-4.52%	1.85%	-32.71%	11.72%	28.18%	3.11%	-42.00%
EBITDA Q/Q Growth	-155.55%	-20.34%	301.16%	143.60%	-14.48%	11.52%	-491.55%	4.07%	116.52%	24.73%	-76.62%
EBIT Q/Q Growth	-239.30%	-28.51%	2,348.69%	96.34%	-9.10%	7.92%	-433.08%	2.64%	85.37%	19.35%	-48.71%
NOPAT Q/Q Growth	-253.59%	-281.94%	116.93%	13.71%	-3.52%	-7.20%	-1,016.83%	122.96%	44.65%	37.06%	-717.77%
Net Income Q/Q Growth	-582.02%	-43.64%	341.53%	87.41%	-23.09%	21.30%	-330.11%	-7.52%	78.57%	1.00%	15.31%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	22.19%	42.39%	-191.58%	25.67%	7.12%	-215.66%	9,170.96%	98.39%	28.38%	1.91%	-180.87%
Free Cash Flow Firm Q/Q Growth	-86.83%	-5.40%	-20.72%	1,269.08%	-68.83%	93.00%	672.14%	-101.83%	185.04%	-24.29%	-40.44%
Invested Capital Q/Q Growth	-1.05%	-1.55%	-0.51%	-2.26%	-9.69%	-0.73%	-6.74%	13.89%	-11.48%	1.32%	-1.47%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	28.42%	46.10%	23.11%	28.35%	24.22%	24.58%	26.70%	47.65%	41.78%	30.21%	17.41%
EBITDA Margin	-25.79%	37.91%	50.33%	11.96%	-28.77%	-24.00%	-27.62%	4.75%	5.10%	-39.53%	-54.16%
Operating Margin	-44.79%	-18.05%	8.19%	-33.85%	-41.15%	-37.96%	-36.06%	2.65%	-12.88%	-29.82%	-48.86%
EBIT Margin	-41.74%	24.47%	36.20%	-1.53%	-43.94%	-38.45%	-42.53%	-5.37%	-6.16%	-53.97%	-69.00%
Profit (Net Income) Margin	-45.09%	7.64%	14.33%	-5.66%	-47.12%	-36.55%	-47.30%	-7.40%	-7.69%	-45.99%	-47.90%
Tax Burden Percent	92.15%	40.09%	51.40%	97.36%	98.38%	91.71%	107.78%	119.39%	107.47%	83.41%	68.12%
Interest Burden Percent	117.23%	77.86%	77.04%	378.68%	109.01%	103.64%	103.18%	115.44%	116.13%	102.16%	101.89%
Effective Tax Rate	0.00%	59.87%	48.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-16.19%	-3.65%	2.09%	-11.39%	-16.38%	-14.58%	-13.96%	0.98%	-5.14%	-12.34%	-24.46%
ROIC Less NNEP Spread (ROIC-NNEP)	-54.85%	67.02%	224.05%	118.68%	-863.97%	-33.17%	-139.89%	-297.41%	13.75%	-73.97%	-310.19%
Return on Net Nonoperating Assets (RNNOA)	-2.28%	1.88%	1.25%	2.05%	-2.31%	-2.20%	-2.85%	-1.50%	0.14%	-3.44%	-1.57%
Return on Equity (ROE)	-18.46%	-1.77%	3.34%	-9.34%	-18.69%	-16.78%	-16.80%	-0.52%	-5.00%	-15.78%	-26.04%
Cash Return on Invested Capital (CROIC)	-2.33%	7.01%	4.51%	7.59%	-4.96%	-0.09%	-1.53%	-7.77%	11.88%	-0.90%	2.09%
Operating Return on Assets (OROA)	-14.03%	8.29%	11.94%	-0.53%	-16.96%	-15.89%	-17.23%	-2.06%	-2.51%	-23.73%	-36.27%
Return on Assets (ROA)	-15.15%	2.59%	4.73%	-1.96%	-18.18%	-15.10%	-19.15%	-2.84%	-3.13%	-20.22%	-25.18%
Return on Common Equity (ROCE)	-18.46%	-1.77%	3.34%	-9.34%	-18.69%	-16.78%	-16.80%	-0.52%	-5.00%	-15.78%	-26.04%
Return on Equity Simple (ROE_SIMPLE)	-2.97%	0.00%	-9.53%	-17.42%	-20.15%	0.00%	-14.37%	-13.63%	-18.77%	0.00%	-19.46%
Net Operating Profit after Tax (NOPAT)	-47	-13	7.31	-43	-50	-48	-45	4.92	-21	-39	-61
NOPAT Margin	-31.36%	-7.24%	4.21%	-23.70%	-28.81%	-26.57%	-25.24%	1.85%	-9.01%	-20.87%	-34.20%
Net Nonoperating Expense Percent (NNEP)	38.67%	-70.66%	-221.96%	-130.07%	847.58%	18.58%	125.94%	298.39%	-18.90%	61.63%	285.73%
Return On Investment Capital (ROIC_SIMPLE)	-2.69%	-0.74%	-	-	-	-2.96%	-	-	-	-2.14%	-
Cost of Revenue to Revenue	71.58%	53.90%	76.89%	71.65%	75.78%	75.42%	73.30%	52.35%	58.22%	69.79%	82.59%
SG&A Expenses to Revenue	39.40%	36.50%	56.56%	37.78%	40.40%	40.07%	40.45%	30.06%	31.84%	39.93%	44.33%
R&D to Revenue	20.57%	16.57%	16.57%	13.22%	12.63%	10.66%	10.88%	6.84%	13.72%	10.54%	10.45%
Operating Expenses to Revenue	73.22%	64.15%	14.92%	62.20%	65.37%	62.53%	62.76%	45.01%	54.66%	60.03%	66.27%
Earnings before Interest and Taxes (EBIT)	-63	45	63	-2.80	-76	-70	-76	-14	-15	-100	-124
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-39	70	87	22	-50	-44	-49	13	12	-73	-97
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.85	0.73	0.74	0.62	0.67	0.84	0.86	1.09	0.73	0.62	0.90
Price to Tangible Book Value (P/TBV)	4.18	40.81	33.35	78.49	0.00	0.00	0.00	10.76	7.48	0.00	6.62
Price to Revenue (P/Rev)	1.62	1.41	1.46	1.22	1.05	1.35	1.43	1.93	1.24	0.96	1.20
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.85	0.72	0.73	0.69	0.78	0.85	0.86	1.09	0.84	0.63	0.89
Enterprise Value to Revenue (EV/Rev)	1.60	1.33	1.36	1.29	1.33	1.50	1.53	2.05	1.33	1.03	1.18
Enterprise Value to EBITDA (EV/EBITDA)	7.87	7.38	62.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	26.00	33.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	9.58	15.02	8.20	0.00	0.00	0.00	0.00	6.38	0.00	40.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.33	0.32	0.31	0.14	0.28	0.17	0.17	0.16	0.15	0.16	0.14
Long-Term Debt to Equity	0.25	0.31	0.30	0.13	0.26	0.15	0.15	0.14	0.14	0.13	0.09
Financial Leverage	0.04	0.03	0.01	0.02	0.00	0.07	0.02	0.01	0.01	0.05	0.01
Leverage Ratio	1.60	1.53	1.51	1.41	1.48	1.42	1.39	1.39	1.41	1.41	1.37
Compound Leverage Factor	1.88	1.19	1.17	5.35	1.61	1.47	1.44	1.61	1.64	1.44	1.39
Debt to Total Capital	24.97%	24.13%	23.76%	12.44%	21.65%	14.82%	14.42%	13.57%	13.19%	13.65%	12.64%
Short-Term Debt to Total Capital	6.49%	0.83%	0.73%	1.40%	1.44%	1.67%	1.78%	1.62%	1.36%	2.02%	5.04%
Long-Term Debt to Total Capital	18.48%	23.29%	23.04%	11.04%	20.21%	13.14%	12.64%	11.95%	11.82%	11.63%	7.60%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	75.03%	75.87%	76.24%	87.56%	78.35%	85.18%	85.58%	86.43%	86.81%	86.35%	87.36%
Debt to EBITDA	3.11	3.37	28.11	-1.64	-2.66	-3.54	-2.49	-1.65	-1.10	-0.91	-0.98
Net Debt to EBITDA	-0.09	-0.41	-4.47	-0.46	-1.76	-1.90	-0.87	-0.72	-0.39	-0.24	0.10
Long-Term Debt to EBITDA	2.31	3.25	27.25	-1.45	-2.48	-3.14	-2.18	-1.46	-0.99	-0.77	-0.59
Debt to NOPAT	-4.22	-4.08	-3.32	-1.06	-2.50	-2.20	-2.43	-2.07	-1.83	-1.56	-1.44
Net Debt to NOPAT	0.12	0.49	0.53	-0.30	-1.66	-1.18	-0.85	-0.90	-0.65	-0.41	0.14
Long-Term Debt to NOPAT	-3.12	-3.94	-3.22	-0.94	-2.33	-1.95	-2.13	-1.82	-1.64	-1.33	-0.87
Altman Z-Score	-0.11	0.05	0.07	-0.15	-0.40	0.10	0.28	0.90	0.41	0.19	0.82
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.49	3.43	2.97	1.63	1.92	1.55	1.78	1.92	1.83	1.85	1.55
Quick Ratio	1.80	2.85	2.42	0.66	0.92	0.62	1.28	1.41	1.04	1.31	1.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	25	192	203	257	19	60	31	-5.45	298	104	138
Operating Cash Flow to CapEx	-1,105.02%	-831.63%	-971.14%	-366.29%	-800.50%	-2,700.56%	787.75%	-6.07%	-745.70%	-537.21%	-461.77%
Free Cash Flow to Firm to Interest Expense	1.64	13.51	11.72	31.37	2.44	17.41	9.21	-1.66	87.79	31.63	45.73
Operating Cash Flow to Interest Expense	-2.23	-3.12	-4.44	-3.23	-4.63	-11.09	9.78	-0.11	-6.68	-9.58	-10.68
Operating Cash Flow Less CapEx to Interest Expense	-2.44	-3.49	-4.90	-4.11	-5.21	-11.50	8.54	-1.95	-7.57	-11.36	-13.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.34	0.33	0.35	0.39	0.41	0.41	0.38	0.41	0.44	0.53
Accounts Receivable Turnover	6.64	5.91	6.35	4.53	6.87	6.89	7.21	4.70	5.46	5.19	6.45
Inventory Turnover	7.63	8.08	8.30	7.92	7.99	7.80	7.66	7.07	6.98	8.92	9.54
Fixed Asset Turnover	10.19	9.80	9.46	9.84	11.03	10.91	0.00	11.02	11.21	12.35	0.00
Accounts Payable Turnover	7.21	8.47	8.23	6.23	7.10	7.98	9.22	7.71	6.99	9.61	12.20
Days Sales Outstanding (DSO)	54.93	61.78	57.47	80.58	53.15	52.98	50.66	77.66	66.84	70.32	56.59
Days Inventory Outstanding (DIO)	47.87	45.20	43.97	46.08	45.66	46.77	47.67	51.64	52.27	40.93	38.24
Days Payable Outstanding (DPO)	50.65	43.08	44.36	58.55	51.38	45.73	39.57	47.34	52.24	37.99	29.91
Cash Conversion Cycle (CCC)	52.16	63.90	57.08	68.11	47.43	54.02	58.75	81.96	66.87	73.26	64.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,299	1,313	1,334	1,341	1,372	1,519	1,530	1,640	1,440	1,627	1,606
Invested Capital Turnover	0.52	0.50	0.50	0.48	0.57	0.55	0.55	0.53	0.57	0.59	0.72
Increase / (Decrease) in Invested Capital	-72	-206	-196	-300	-69	-108	-76	10	-319	-143	-199
Enterprise Value (EV)	1,102	951	970	927	1,066	1,297	1,322	1,782	1,212	1,032	1,436
Market Capitalization	1,115	1,003	1,039	871	836	1,167	1,237	1,677	1,128	966	1,459
Book Value per Share	$1.95	$2.00	$2.01	$2.00	$1.80	$1.80	$1.87	$1.99	$2.01	$2.02	$2.11
Tangible Book Value per Share	$0.40	$0.04	$0.04	$0.02	($0.22)	($0.19)	($0.13)	$0.20	$0.20	($0.07)	$0.29
Total Capital	1,748	1,800	1,841	1,594	1,599	1,631	1,688	1,776	1,788	1,809	1,865
Total Debt	436	434	437	198	346	242	243	241	236	247	236
Total Long-Term Debt	323	419	424	176	323	214	213	212	211	210	142
Net Debt	-12	-52	-70	56	229	130	85	105	84	66	-23
Capital Expenditures (CapEx)	3.13	5.34	7.94	7.22	4.44	1.42	4.20	6.01	3.04	5.89	6.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)	119	52	25	120	134	41	48	128	98	64	60
Debt-free Net Working Capital (DFNWC)	555	484	431	161	210	137	187	236	208	218	241
Net Working Capital (NWC)	442	469	418	138	187	109	157	207	184	181	147
Net Nonoperating Expense (NNE)	21	-27	-18	-33	32	18	39	25	-3.15	47	25
Net Nonoperating Obligations (NNO)	-12	-52	-70	-55	119	130	85	105	-111	66	-23
Total Depreciation and Amortization (D&A)	24	25	25	25	26	26	27	27	27	27	27
Debt-free, Cash-free Net Working Capital to Revenue	17.28%	7.30%	3.51%	16.77%	16.80%	4.73%	5.56%	14.74%	10.69%	6.42%	4.90%
Debt-free Net Working Capital to Revenue	80.52%	67.87%	60.64%	22.44%	26.26%	15.83%	21.55%	27.19%	22.83%	21.67%	19.72%
Net Working Capital to Revenue	64.08%	65.76%	58.75%	19.32%	23.38%	12.67%	18.07%	23.88%	20.16%	18.03%	12.02%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.10)	$0.01	$0.04	($0.01)	($0.12)	($0.09)	($0.11)	($0.03)	($0.02)	($0.13)	($0.11)
Adjusted Weighted Average Basic Shares Outstanding	671.58M	694.02M	694.62M	697.21M	706.88M	751.77M	751.53M	751.73M	751.51M	719.06M	750.40M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.03	$0.00	$0.00	$0.00	$0.00	$0.00	($0.02)	$0.00	($0.11)
Adjusted Weighted Average Diluted Shares Outstanding	793.05M	671.55M	998.36M	697.38M	696.99M	696.99M	773.06M	773.06M	751.51M	772.65M	750.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	793.05M	671.55M	682.48M	697.38M	696.99M	696.99M	773.06M	773.06M	772.65M	772.65M	772.69M
Normalized Net Operating Profit after Tax (NOPAT)	-47	-108	7.31	-43	-50	-48	-46	4.89	-21	-41	-62
Normalized NOPAT Margin	-31.36%	-58.94%	4.21%	-23.70%	-28.81%	-26.57%	-25.69%	1.84%	-8.97%	-22.32%	-34.49%
Pre Tax Income Margin	-48.93%	19.05%	27.89%	-5.81%	-47.89%	-39.85%	-43.89%	-6.20%	-7.15%	-55.13%	-70.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.05	3.16	3.62	-0.34	-9.93	-20.25	-22.45	-4.35	-4.32	-30.29	-41.11
NOPAT to Interest Expense	-3.04	-0.93	0.42	-5.28	-6.51	-13.99	-13.32	1.50	-6.32	-11.72	-20.38
EBIT Less CapEx to Interest Expense	-4.25	2.78	3.16	-1.22	-10.51	-20.66	-23.69	-6.18	-5.21	-32.07	-43.42
NOPAT Less CapEx to Interest Expense	-3.24	-1.31	-0.04	-6.16	-7.09	-14.40	-14.57	-0.33	-7.21	-13.50	-22.69
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-103.13%	-169.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About OPKO Health's Financials

When does OPKO Health's financial year end?

According to the most recent income statement we have on file, OPKO Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has OPKO Health's net income changed over the last 10 years?

OPKO Health's net income appears to be on a downward trend, with a most recent value of -$53.22 million in 2024, falling from -$174.64 million in 2014. The previous period was -$188.86 million in 2023. Check out OPKO Health's forecast to explore projected trends and price targets.

What is OPKO Health's operating income?

OPKO Health's total operating income in 2024 was -$152.07 million, based on the following breakdown:

Total Gross Profit: $218.51 million
Total Operating Expenses: $370.58 million

How has OPKO Health revenue changed over the last 10 years?

Over the last 10 years, OPKO Health's total revenue changed from $91.15 million in 2014 to $713.14 million in 2024, a change of 682.4%.

How much debt does OPKO Health have?

OPKO Health's total liabilities were at $834.76 million at the end of 2024, a 34.1% increase from 2023, and a 83,476,400,000.0% increase since 2014.

How much cash does OPKO Health have?

In the past 10 years, OPKO Health's cash and equivalents has ranged from $0.00 in 2014 to $431.94 million in 2024, and is currently $431.94 million as of their latest financial filing in 2024.

How has OPKO Health's book value per share changed over the last 10 years?

Over the last 10 years, OPKO Health's book value per share changed from 0.00 in 2014 to 2.00 in 2024, a change of 200.1%.

Related Companies

This page (NASDAQ:OPK) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Financials

Frequently Asked Questions About OPKO Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Financials

Annual Income Statements for OPKO Health

Quarterly Income Statements for OPKO Health

Annual Cash Flow Statements for OPKO Health

Quarterly Cash Flow Statements for OPKO Health

Annual Balance Sheets for OPKO Health

Quarterly Balance Sheets for OPKO Health

Annual Metrics And Ratios for OPKO Health

Quarterly Metrics And Ratios for OPKO Health

Frequently Asked Questions About OPKO Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools